Skip to content

US · SMMT · BIOTECHNOLOGY

Summit Therapeutics Inc. (SMMT) intrinsic value and stock valuation

$9.95as of 2026-11-21 · Mkt cap 11.14B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Summit Therapeutics Inc. DCF and intrinsic value

InvestorsCraft values SMMT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SMMT’s statements →

Summit Therapeutics Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Miami, FL 33131 smmttx.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-1.08B
20112025
Free cash flow
-$-240.15M
20112025
Total equity
$489M+53% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$580K$1.34M
Operating income-$-1.09B-$-180.51M-$-478.23M-$-59.63M-$-63.73M
Net income-$-1.08B-$-176.77M-$-482.37M-$-65.17M-$-65.52M
EPSd-$-1.44M-$-246.01K-$-778.46K-$-337.07K-$-710.32K
Operating cash flow-$-239.67M-$-113.56M-$-60.74M-$-33.9M-$-53.81M
Capital expenditure-$-490K-$-110K-$-100K-$-510K-$-230K
Free cash flow-$-240.15M-$-113.67M-$-60.85M-$-34.41M-$-54.03M
Total assets$557.5M$348.1M$160.6M$541.4M$84M
Total debt$15.5M$5.77M$84M$422.9M$2.06M
Net debt-$-151.68M-$-78.03M$27.4M$138.7M-$-51.15M
Total equity$489M$310.6M$61.5M$103.3M$61.7M
Cash and short-term investments$529.5M$329.5M$147.4M$284.2M$53.2M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$580K$1.34M
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$580K$1.34M
Research and development expenses$537.7M$132.4M$455.3M$43M$63.1M
Selling, general and administrative expenses$556.7M$48.4M$23.7M$22.1M$17.5M
Other expenses$0.00-$-250K-$-790K-$-4.92M-$-15.51M
Operating expenses$1.09B$180.5M$478.2M$60.2M$65.1M
Cost and expenses$1.09B$180.5M$478.2M$60.2M$65.1M
Interest income$15.5M$13.5M$10.4M$1.51M$0.00
Interest expense$0.00$8.69M$16.5M$4.4M$210K
Depreciation and amortization$150K$70K$160K$1.04M$1M
Ebitda-$-1.08B-$-168.46M-$-69.45M-$-51.58M-$-64.31M
Operating income-$-1.09B-$-180.51M-$-478.23M-$-59.63M-$-63.73M
Total other income/expenses, net$14.8M$3.74M-$-4.14M-$-5.54M-$-1.79M
Income before tax-$-1.08B-$-176.77M-$-482.37M-$-65.17M-$-65.52M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-1.08B-$-176.77M-$-482.37M-$-65.17M-$-65.52M
Weighted average shares outstanding$747.7M$713.9M$619.6M$192.2M$92.2M
Weighted average diluted shares outstanding$747.7M$718.5M$619.7M$193.3M$92.2M
Balance sheet
20252024202320222021
Cash and short-term investments$529.5M$329.5M$147.4M$284.2M$53.2M
Net receivables$0.00$450K$670K$4.98M$12.7M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$534.6M$338.6M$150.1M$535.4M$72.1M
Property, plant and equipment, net$16.1M$5.91M$4.8M$4.14M$2.58M
Goodwill and intangible assets$1.49M$1.49M$1.5M$1.47M$9.2M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$22.9M$9.44M$10.5M$6.08M$11.9M
Total assets$557.5M$348.1M$160.6M$541.4M$84M
Accounts payable$15.1M$3.7M$2.11M$290K$3.24M
Short-term debt$2.51M$3.01M$2.22M$17.5M$810K
Deferred revenue$0.00$0.00$0.00$0.00$5.88M
Total current liabilities$54.2M$33.4M$16.2M$31.6M$19M
Long-term debt$13M$2.76M$81.7M$405.4M$1.25M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$14.4M$4.06M$83M$406.6M$3.31M
Capital lease obligations$15.5M$5.77M$4.83M$3.63M$2.06M
Total liabilities$68.5M$37.4M$99.1M$438.2M$22.3M
Common stock$5.75M$5.89M$5.55M$1.72M$730K
Retained earnings-$-1.7B-$-970.55M-$-786.02M-$-308.41M-$-222.05M
Accumulated other comprehensive income (loss)-$-1.89M-$-1.83M-$-1.94M-$-1.54M-$-1.63M
Total equity$489M$310.6M$61.5M$103.3M$61.7M
Total investments$362.3M$245.7M$90.9M$0.00$0.00
Total debt$15.5M$5.77M$84M$422.9M$2.06M
Net debt-$-151.68M-$-78.03M$27.4M$138.7M-$-51.15M
Cash flow statement
20252024202320222021
Net income-$-801.23M-$-176.85M-$-486.63M-$-64.22M-$-65.68M
Depreciation and amortization$110K$70K$160K$1.03M$1.82M
Stock-based compensation$543.6M$40.7M$11.2M$9.74M$9.49M
Change in working capital$23.3M$12.4M-$-410K$8.04M-$-50K
Accounts receivable$0.00$430K$3.58M$7.67M-$-5.3M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$11.4M$1.61M$1.79M-$-3.37M-$-1.27M
Net cash provided by operating activities-$-239.67M-$-113.56M-$-60.74M-$-33.9M-$-53.81M
Investments in property, plant and equipment-$-490K-$-110K-$-100K-$-510K-$-230K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-129.37M-$-164.09M-$-465.14M-$-510K-$-230K
Common stock issued$458.3M$384.5M$88.5M$81.8M$57.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$458.3M$304.6M$68.5M$505.6M$57.8M
Net change in cash$89.4M$27M-$-456.76M$470.2M$3.98M
Cash at end of period$167.4M$84.1M$56.5M$528.7M$53.2M
Operating cash flow-$-239.67M-$-113.56M-$-60.74M-$-33.9M-$-53.81M
Capital expenditure-$-490K-$-110K-$-100K-$-510K-$-230K
Free cash flow-$-240.15M-$-113.67M-$-60.85M-$-34.41M-$-54.03M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Summit Therapeutics Inc.

        Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.

        CEO
        Robert W. Duggan
        Employees
        265
        Beta
        -1.26

        Explore

        Frequently asked questions

        What is the intrinsic value of Summit Therapeutics Inc. (SMMT)?

        InvestorsCraft does not currently publish an intrinsic value for SMMT. How the IC value is calculated.

        Is SMMT undervalued?

        InvestorsCraft does not publish an undervaluation signal for SMMT at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.